1. Improving Outcomes in Psoriatic Arthritis

3. This program will include a discussion of investigational agents not approved by the FDA for use in the US.

4. Introduction

5. Key Cells and Mediators in Psoriasis Transition From Innate to Adaptive Immunity

6. Pathophysiology of Psoriatic Arthritis

7. Role of IL-17 Signaling

8. IL-17 Inhibitors

9. Secukinumab, Anti IL-17A For the Treatment of Psoriasis

10. Secukinumab PsA

11. FUTURE 1 and FUTURE 2 Results

12. FUTURE 2: Efficacy of Secukinumab in Anti-TNF-Naïve and Anti-TNF-IR Patients

13. FUTURE 5 Improvement in Radiographic Progression

14. Summary of Pooled Safety Across FUTURE 1 and FUTURE 2 Studies

15. Ixekizumab for the Treatment of Psoriasis and Psoriatic Arthritis

16. Ixekizumab Psoriasis

17. Ixekizumab for the Treatment of PsA SPIRIT-P1

18. SPIRIT-P2: Ixekizumab for the Treatment of PsA in TNF-IR Patients

19. Frequency of Adverse Events Across SPIRIT-P1 and SPIRIT-P2 Studies

20. Brodalumab Psoriasis

21. Brodalumab Phase II Trial Findings in Patients With PsA

22. Bimekizumab PsA

23. Future Landscape of Psoriasis and PsA Treatments

24. Factors to Consider When Deciding on a Treatment Plan

25. PREPARE Study

26. Diagnosing PsA in Patients With Psoriasis

27. Early Referral to Rheumatology

28. Address Comorbidities in Psoriasis and PsA

29. Concluding Remarks

30. Abbreviations

31. Abbreviations (cont)

32. Abbreviations (cont)